Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in <i>Plasmodium berghei</i>-Infected Mice

<div>Blood film of PbANKA infection in mice treated with DMSO (a), PYR (b), DFP (c), and DFPRVT (d). Male ICR mice (<i>n</i> = 3 each) were intraperitoneally infected with pRBC suspension (approximately 1 × 10<sup>7</sup> cells/mL with 10−20% parasitemia) and orally administered with 60% DMSO, PYR (2 mg/kg BW), DFP (50 mg/kg BW), and DFP-RVT (50 mg/kg BW) everyday for 8 consecutive days. Blood-stage percentage of pRBC was determined using the microscopic Giemsa staining method. BW = body weight, DFP = deferiprone, DFP-RVT = deferiprone-resveratrol, DMSO = dimethylsulfoxide, PbANKA = <i>P. berghei</i> ANKA strain, pRBC = parasitized red blood cell, and PYR = pyrimethamine.</div>

Bioinorganic Chemistry and Applications

fig2

Figure 2

Figure 2: Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in <i>Plasmodium berghei</i>-Infected Mice 

Figure 2 | Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei-Infected Mice 